Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
172
days
Stem cell source, CD34+ dose and outcomes in haploidentical hematopoietic cell transplantation for myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT
Authors
Tomasz Czerw; Luuk Gras; Laurien GA Baaij; Massimiliano Gambella; Didier Blaise; Patrizia Chiusolo; Mi Kwon; Jakob Passweg; Alessandro Busca; Sandrine Loron; Patrice Ceballos; Mohamad Mohty; Fabio Ciceri; Radovan Vrhovac; Antonio Bianchessi; Matteo Parma; Hakan Ozdogu; Johannes Clausen; Linda Koster; Joanna Drozd-Sokolowska; Kavita Raj; Giorgia Battipaglia; Nicola Polverelli; Donal P. McLornan; Juan Carlos Hernández-BoludaShow moreShow less
Affiliations
1. Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland; 2. EBMT Leiden Study Unit, Leiden, the Netherlands; 3. IRCCS Ospedale Policlinico San Martino, Genova, Italy; 4. Programme de Transplantation & Therapie Cellulaire, Marseille, France; 5. Dipartimento di Scienze di Laboratorio ed Ematologiche-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica del Sacro Cuore-, Roma, Italy; 6. Hospital Gregorio Marañón, Madrid, Spain; 7. University Hospital Basel, Basel, Switzerland; 8. S.S.C.V.D Trapianto di Cellule Staminali, Torino, Italy; 9. Centre Hospitalier Lyon Sud, Lyon, France; 10. CHU Lapeyronie, Montpellier, France; 11. Hopital Saint Antoine, Paris, France; 12. Ospedale San Raffaele s.r.l, Milano, Italy; 13. University Hospital Centre Zagreb, Zagreb, Croatia; 14. Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 15. Ospedale San Gerardo, Monza, Italy; 16. Baskent University Hospital, Adana, Turkey; 17. Elisabethinen-Hospital, Linz, Austria; 18. Central Clinical Hospital, The Medical University of Warsaw, Warsaw, Poland; 19. University College London Hospitals NHS Trust, London, UK; 20. Hematology Department, Federico II University of Naples, Naples, Italy; 21. Department of Hematology, Hospital Clínico Universitario, Valencia, SpainShow moreShow less
131
days
Optimal levetiracetam dosage regimen for preventing seizures related to immune effector cell-associated neurotoxicity syndrome
Authors
Yuri Sugimoto; Yuichi Tsuchiya; Yudai Wada; Nanae Yamamoto; Hoyumi Uematsu; Daisuke Kobayashi; Takuji Yamauchi; Fumiaki Jinnouchi; Teppei Sakoda; Kohta Miyawaki; Takahiro Shima; Ken Takigawa; Masatoshi Shimo; Yoshikane Kikushige; Yasuo Mori; Satoshi Nakao; Takahiro Nakamura; Masatoshi Mine; Koichi Akashi; Takeshi Hirota; Mayako Uchida; Koji KatoShow moreShow less
Affiliations
1. Department of Pharmacy, Kyushu University Hospital, Higashi-ku, Japan; 2. Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Japan; 3. Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Japan; 4. Department of Hematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Higashi-ku, JapanShow moreShow less
95
days
Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition
Authors
Philipp Berning; Christophe Peczynski; Jan C. Schroeder; Eva Michel; Michael Oertel; Fizza Imran; Evgenii Shumilov; Imke E. Karsten; Robin Sanderson; Urban Novak; Ron Ram; Peter Dreger; David Beauvais; Maxime Delforge; Daniela Taurino; Robin Noel; Almudena Cabero; Ralph Wäsch; Malte von Bonin; Peter Vandenberghe; Olaf Penack; Björn Chapuy; Avichai Shimoni; Barbara Dreta; Ulf Schnetzke; Eugenio Galli; Anna Ossami Saidy; Georg Lenz; Bertram Glass; Anna Sureda; Ali Bazarbachi; Wolfgang Bethge; Norbert SchmitzShow moreShow less
Affiliations
1. Department of Medicine A, University Hospital Münster, Münster, Germany; 2. European Society for Blood and Marrow Transplantation, Paris Office, Paris, France; 3. University Hospital and Comprehensive Cancer Center Tübingen, Department for Hematology, Oncology, Clinical Immunology and Rheumatology, Tübingen, Germany; 4. Department of Radiation Oncology, University Hospital Münster, Münster, Germany; 5. King’s College Hospital, London, UK; 6. Department of Medical Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland; 7. BMT Unit, Tel Aviv Sourasky Medical Center and Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel; 8. University of Heidelberg, Heidelberg, Germany; 9. Department of Hematology, CHU Lille, Lille, France; 10. IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milano, Rozzano, Milano, Italy; 11. Programme de Transplantation & Thérapie Cellulaire, Marseille, France; 12. Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain; 13. University of Freiburg, Freiburg, Germany; 14. Universitätsklinikum Dresden, Dresden, Germany; 15. University Hospitals Leuven, Leuven, Belgium; 16. Department of Hematology, Oncology, and Cancer Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany; 17. German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany; 18. Chaim Sheba Medical Center, Tel-Hashomer, Israel; 19. University Hospital Center Rebro, Zagreb, Croatia; 20. Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; 21. Dipartimento di Scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 22. Helios Klinikum Berlin-Buch, Berlin, Germany; 23. Hematology Department, Institut Català d’Oncologia, Barcelona-L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; 24. Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, LebanonShow moreShow less
350
days
Outcomes of autologous cord blood transplantation followed by cyclosporine A monotherapy in pediatric aplastic anemia: A single-center experience and pooled analysis
Authors
Chaoqian Jiang; Xia Chen; Luyang Zhang; Yuanyuan Ren; Lipeng Liu; Yue Shang; Xin Wang; Yumei Chen; Li Zhang; Yao Zou; Fang Liu; Xiaojuan Chen; Wenyu Yang; Xiaofan Zhu; Ye GuoShow moreShow less
Affiliations
1. Department of Pediatric Hematology and Oncology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; 2. Tianjin Institutes of Health Science, Tianjin, ChinaShow moreShow less
246
days
Cryopreservation of academic CAR T-cell products: methodological recommendations from the EBMT practice harmonisation and guidelines committee
Authors
Halvard Bonig; Boris Calmels; Camille Giverne; Ulrike Köhl; Jürgen Kuball; Chantal Lechanteur; Francesco Onida; Isabel Sánchez-Ortega; Annalisa Ruggeri; Trudy Straetemans; Nina Worel; Ibrahim Yakoub-AghaShow moreShow less
Affiliations
1. Institute for Transfusion Medicine and Immunohematology, Goethe University and German Red Cross Blood Service BaWueHe, Frankfurt, Germany; 2. Centre de Thérapie Cellulaire, Institut Paoli-Calmettes, INSERM CIC Biothérapie BT-510, Marseille, France; 3. CHU de Rouen, laboratoire d’Immunologie et Biothérapies, Université de Rouen Normandie, INSERM, UMR 1234, Rouen, France; 4. Fraunhofer Institute of Cell therapy and Immunology; Institute of Clinical Immunology, University and University hospital, Leipzig, Germany; 5. Center for Translational Immunology, & Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands; 6. Laboratoire de thérapie cellulaire et génique (LTCG), Hématologie Clinique, CHU de Liège, Liège, Belgique; 7. Hematology and BMT Unit, ASST Fatebenefratelli-Sacco, Dept. of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; 8. Co chair of the EBMT Practice Harmonisation Committee, Barcelona, Spain; 9. EBMT Chief Medical Officer, Barcelona, Spain; 10. Secretary of the EBMT Practice Harmonisation and Guidelines Committee, Barcelona, Spain; 11. Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; 12. Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria; 13. CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France; 14. Chair of the EBMT Practice Harmonisation and Guidelines Committee, Barcelona, SpainShow moreShow less
94
days
Pre-transplant IFD history influences the incidence of IFD after allogeneic haematopoietic stem cell transplantation
Authors
Danping Zhu; Liyun Chen; Xiaoyu Zhu; Nainong Li; Weijie Cao; Zhongming Zhang; Yehui Tan; Xiaoxia Hu; Hailong Yuan; Xiaosheng Fang; Yue Yin; Hongtao Wang; Xiaojun Huang; Jia Chen; Yuqian SunShow moreShow less
Affiliations
1. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 2. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; 3. Department of Hematology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China; 4. Department of Hematology, Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China; 5. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 6. Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China; 7. Department of Hematology, The First Affiliated Hospital of Jilin University, Changchun, China; 8. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 9. The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology, Urumqi, China; 10. Department of Hematology, Shandong First Medical University Affiliated Provincial Hospital, Jinan, China; 11. Department of Hematology, Peking University First Hospital, Beijing, China; 12. Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, ChinaShow moreShow less
FAQ
How long does BONE MARROW TRANSPLANTATION take to review a manuscript?
As of 2026-11-18, CrushSCI has 20 complete review records for BONE MARROW TRANSPLANTATION. The fastest paper went from submission to acceptance in 24 days (PTCy-based GVHD prophylaxis helps navigate donor selection in secondary AML undergoing alternative donor transplantation, received 2026-07-20, accepted 2026-08-13); the slowest took 350 days. The average is 156.7 days and the median is 141.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
